Skip to content

Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.

Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure. The ENDOLUNG Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02542423
Enrollment
150
Registered
2015-09-07
Start date
2015-09-30
Completion date
2017-03-31
Last updated
2015-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Complications, Respiratory Failure

Brief summary

According to literature data, Endocan can detect the onset of respiratory failure. The investigators aim to prove its value also for cardiac surgery patients.

Detailed description

Endocan is an endothelium derived soluble dermatan sulfate proteoglycan. Literature data shows that alterate levels of its blood concentration correlate with the onset of pulmonary failure in patients with major trauma and septic shock. In cardiac surgery respiratory failure and infections are threatening complications leading to mortality rates up to 80%. A rapid diagnosis and treatment of this pathology is crucial to improve the clinical outcome. Unfortunately specific data for the efficacy of Endocan predictive value in cardiac surgery patients are not available. The investigators aim to determinate if Endocan can be a helpful tool to identify patients developing acute respiratory failure after cardiac surgery and anticipate specific treatment in order to improve survival.

Interventions

OTHEREndocan blood test samples

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Able to give written consent * Elective cardiac surgery * More than 18 years old

Exclusion criteria

* Less than 18 years old * urgency / emergency cardiac surgery * pregnancy * refusal * unable to give written consent * oncologic patients * concomitant inflammatory or infective pulmonary disease

Design outcomes

Primary

MeasureTime frameDescription
Changes of Endocan blood levels after cardiac surgery and its correlation with postoperative pulmonary failurefrom day -1 of the intervention to day 3, one blood sample per dayThe investigators will enroll 150 patients undergoing elective cardiac surgery. Every participant will be prelevated of several blood samples following this time frame : day -1 from intervention, day 0 ( six hours after intervention), day 1 , day 2 , day 3. All patients will be observed to detect all infections, especially pulmonary ones, up to hospital discharge. Endocan blood levels of patients developing pulmonary failure and patients without postoperative respiratory insufficiency will be compared.

Contacts

Primary ContactSidney Chocron, MD Ph D
sidney.chocron@univ-fcomte.fr+33381668662
Backup ContactAndrea Perrotti, MD
a.perrotti@hotmail.it+33381669416

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026